Cover image of HT1 guidelines


Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
May 2019
Publication type: 
Intended audience: 
Health sector

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of hereditary tyrosinaemia (type 1) through the LSDP
  • Drugs currently available for the treatment of hereditary tyrosinaemia (type 1) through the LSDP
  • Choice of treatment
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.